Assessment of ALK gene rearrangement in lung cancer using a new rapid automated SureFISH (Dako Omnis) assay. Issue 8 (6th March 2017)

• Record Type: Journal Article
• Authors: Takeda, Maiko; Kasai, Takahiko; Shimizu, Shigeki; Kitaichi, Masanori; Kojima, Kensuke; Nagoya, Akihiro; Hayashi, Akio; Utsumi, Tomoki; Yoon, Hyung-Eun; Matsumura, Akihide; Atagi, Shinji
• Is Part Of: Journal of clinical pathology. Volume 70:Issue 8(2017)
• Page Start: 712
• Page End: 714
• Publication Date: 2017-03-06
• Subjects: LUNG CANCER -- FISH -- MOLECULAR PATHOLOGY; Pathology -- Periodicals; Pathology, Molecular -- Periodicals; 616.0705
• DOI: 10.1136/jclinpath-2016-204311
• Languages: English
• ISSNs: 0021-9746

Abstract

Abstract : The ALK fluorescence in situ hybridisation (FISH) method is the examination essential for pathological diagnosis and choice of molecular-targeted therapy in ALK -rearranged lung cancer. Here, for detection of ALK gene rearrangement in patients with lung cancer, we evaluated the rapid FISH technology ( ALK SureFISH), a newly developed assay for the automated staining platform Dako Omnis, using 21 formalin-fixed paraffin-embedded (FFPE) samples. All cases could be evaluated with the SureFISH method. SureFISH provided excellent quality signals without any background staining. The SureFISH assay was able to offer a rapid turnaround time (approximately 3.5 hours) and was 100% concordant with prior Vysis FISH results in our laboratory.